0001567619-22-014722.txt : 20220801
0001567619-22-014722.hdr.sgml : 20220801
20220801174000
ACCESSION NUMBER: 0001567619-22-014722
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210203
FILED AS OF DATE: 20220801
DATE AS OF CHANGE: 20220801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peyer James
CENTRAL INDEX KEY: 0001843594
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 221126042
MAIL ADDRESS:
STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC.
STREET 2: 1405 RESEARCH BLVD., STE. 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
3/A
1
doc1.xml
FORM 3/A
X0206
3/A
2021-02-03
2021-02-03
0
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001843594
Peyer James
C/O SENSEI BIOTHERAPEUTICS, INC.
1405 RESEARCH BLVD. SUITE 125
ROCKVILLE
MD
20850
1
0
1
0
Common Stock
2282827
I
See footnote
Series AA Preferred Convertible Stock
Common Stock
110729827
I
See footnote
Series BB Preferred Convertible Stock
Common Stock
4821996
I
See footnote
Stock Option (right to buy)
3.22
2030-08-04
Common Stock
19520
I
See footnote
These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Dr. Peyer disclaims beneficial ownership of such shares.
Each share of the Series AA Preferred Stock and Series BB Preferred Stock is convertible, at any time, at the holder's election, into 0.0208333 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series AA Preferred Stock and Series BB Preferred Stock will automatically convert into 0.0208333 shares of the Issuer's common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date. Dr. Peyer disclaims beneficial ownership of such shares.
The shares subject to the option vest monthly over twenty-four (24) months from the vesting commencement date, March 31, 2020, subject to the continuous service of James Peyer on the Issuer's Board of Directors. Dr. Peyer is the Chief Executive Officer of Cambrian and disclaims beneficial ownership of such shares.
Amendment filed solely to correct the number of shares owned.
/s/ Sarah Field, Attorney-in-Fact
2022-08-01